Search Within

Population Sciences Research Program

  1. "Paul Chapman"
Formats
  1. Journal Article (55)
  2. Meeting Abstract (26)
  3. Book Section (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (82)
  2. Department of Medicine (82)
  3. Melanoma and Immunotherapeutics Service (82)
  4. Solid Tumor Oncology Division (82)
  5. Biostatistics Service (78)
  6. Epidemiology and Biostatistics (78)

More Groups

People
  1. Paul Chapman (82)
  2. Katherine Panageas (76)
  3. Jedd Wolchok (58)
  4. Michael Postow (31)
  5. Alexander Shoushtari (28)
  6. Margaret Callahan (28)

More People

Years
  1. 2023 (3)
  2. 2022 (2)
  3. 2021 (4)
  4. 2020 (5)
  5. 2019 (2)
  6. 2018 (4)

More Years

Publications
  1. Journal of Clinical Oncology (28)
  2. Clinical Cancer Research (9)
  3. Annals of Surgical Oncology (4)
  4. Cancer (4)
  5. Cancer Research (4)
  6. Journal for ImmunoTherapy of Cancer (3)

More Publications

Publishers
  1. American Society of Clinical Oncology (29)
  2. American Association for Cancer Research (14)
  3. Oxford University Press (6)
  4. Wiley Blackwell (6)
  5. Biomed Central Ltd (4)
  6. Springer (4)

More Publishers

Results (82)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT)
    Meeting Abstract

    Smithy, J. W.; Kalvin, H. L.; Raber, V.; Maher, C. A.; Kleman, J.; McIntyre, D. A. G.; Shoushtari, A. N.; Betof Warner, A.; Callahan, M. K.; Momtaz, P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1
    Journal Article

    Loo, K.; Kalvin, H. L.; Panageas, K. S.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Pigment Cell & Melanoma Research (2023)

    Fulltext@MSK | Save
  • Decision-making and health-related quality of life in patients with melanoma considering adjuvant immunotherapy
    Journal Article

    Atkinson, T. M.; Hay, J. L.; Kim, S. Y.; Schofield, E.; Postow, M. A.; Momtaz, P.; Warner, A. B.; Shoushtari, A. N.; Callahan, M. K.; Wolchok, J. D.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Adaptive dosing of nivolumab + ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (The ADAPT-IT study)
    Journal Article

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Betof Warner, A.; Callahan, M. K.; Momtaz, P.; Smithy, J. W.; Naito, E.; Cugliari, M. K.; Raber, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: Clinical outcomes and translational biomarker analyses
    Journal Article

    Friedman, C. F.; Spencer, C.; Cabanski, C. R.; Panageas, K. S.; Wells, D. K.; Ribas, A.; Tawbi, H.; Tsai, K.; Postow, M.; Shoushtari, A.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB)
    Meeting Abstract

    Loo, K.; Goldman, D. A.; Panageas, K.; Callahan, M. K.; Chapman, P. B.; Momtaz, P.; Shoushtari, A. N.; Wolchok, J. D.; Postow, M. A.; Warner, A. B.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Journal Article

    Chapman, P. B.; Jayaprakasam, V. S.; Panageas, K. S.; Callahan, M.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; Betof Warner, A.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
    Journal Article

    Shen, R.; Postow, M. A.; Adamow, M.; Arora, A.; Hannum, M.; Maher, C.; Wong, P.; Curran, M. A.; Hollmann, T. J.; Jia, L.; more...
    Science Translational Medicine (2021)

    Fulltext@MSK | Save
  • Therapeutic implications of detecting MAPK-activating alterations in cutaneous and unknown primary melanomas
    Journal Article

    Shoushtari, A. N.; Chatila, W. K.; Arora, A.; Sanchez-Vega, F.; Kantheti, H. S.; Rojas Zamalloa, J. A.; Krieger, P.; Callahan, M. K.; Betof Warner, A.; Postow, M. A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy
    Meeting Abstract

    Postow, M. A.; Goldman, D. A.; Shoushtari, A. N.; Warner, A. B.; Callahan, M. K.; Momtaz, P.; Naito, E.; Eton, O.; Nair, S.; Wolchok, J. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save